KD Logo

Director SATO VICKI L sale 1,674 shares of Denali Therapeutics Inc [DNLI]

The buying and selling of stock by a company’s insider give investors a sense that the stock will rise or fall in the future. Denali Therapeutics Inc shares valued at $34,133 were sold by SATO VICKI L on May 15 ’24. At $20.39 per share, SATO VICKI L sold 1,674 shares. The insider’s holdings dropped to 116,369 shares worth approximately $2.48 million following the completion of this transaction.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Also, SATO VICKI L sold 1,666 shares, netting a total of over 30,471 in proceeds. Following the sale of shares at $18.29 each, the insider now holds 118,043 shares.

Before that, Krognes Steve E. had sold 92,500 shares from its account. In a trade valued at $1,896,250, the Director traded Denali Therapeutics Inc shares for $20.50 each. Upon closing the transaction, the insider’s holdings decreased to 92,500 shares, worth approximately $1.01 million.

As published in their initiating research note from Citigroup on December 13, 2023, Denali Therapeutics Inc [DNLI] has been a Buy and the price target has been revised to $32. Earlier on September 06, 2023, B. Riley Securities initiated its rating. Their recommendation was “a Buy” for DNLI stock.

Analyzing DNLI Stock Performance

During the last five days, there has been a surge of approximately 15.44%. Over the course of the year, Denali Therapeutics Inc shares have dropped approximately -0.70%. Shares of the company reached a 52-week high of $23.52 on 02/27/24 and a 52-week low of $14.56 on 04/25/24. A 50-day SMA is recorded $18.49, while a 200-day SMA reached $19.59. Nevertheless, trading volume fell to 0.99 million shares from 1.29 million shares the previous day.

Support And Resistance Levels for Denali Therapeutics Inc (DNLI)

According to the 24-hour chart, there is a support level at 21.06, which, if violated, would cause prices to drop to 20.81. In the upper region, resistance lies at 21.78. The next price resistance is at 22.25. RSI (Relative Strength Index) is 63.30 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 1.47, which suggests the price will increase in the coming days. Percent R is at 17.76%, indicating bullish price movement. Stochastics %K at selling indicates that the stock is to be held.

Most Popular